Alan Bao

Counsel

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Alan Bao focuses his practice on mergers and acquisitions, capital markets, and other general corporate matters. He represents clients in their going private, Hong Kong initial public offerings (IPOs), as well as in FIE, employment, and IP enforcement matters.

Alan understands that legal challenges can interrupt companies’ foci from their core business activities. He skillfully crafts solutions that enable his clients to retain energy for business management and development. Alan’s clients range from start-ups to Fortune 500 corporations and operate in a wide variety of industries such as financial services (including investment banks and private equity), consumer electronics and technology, health care, biotechnology, pharmaceuticals, gaming, entertainment, and aviation.

Prior to relocating to Beijing, Alan worked in the firm’s Los Angeles office.

Languages

  • Mandarin
  • Taiwanese

Admissions

Bar Admissions

  • California

Court Admissions

  • US Court of Appeals, District of Central California
  • US District Court, District of Central California
  • Superior Court, District of Central California

Education

  • University of Southern California, J.D.; LL.M.
  • China University of Political Science and Law, LL.B., third-class honors

Professional Activities

Clerkships

  • The People's Supreme Court of People's Republic of China

Externships

  • Honorable Samuel Bufford, US Bankruptcy Court, California (Central)

Member

  • Student Bar Association (President), International Economic Law School, China University of Political Science and Law
  • Los Angeles County Bar Association 

Author

  • “Comparative Studies of China's Enterprise Bankruptcy Law and the U.S. Bankruptcy Law,” Norton Journal of Bankruptcy Law and Practice (2010)
  • “On the Validity of Parallel Import,” People's Judicature, China (2003)
  • “The Legal Infrastructure, Judicial Independence and Economic Development,” The Forum for Civil and Commercial Justice, China (2006) (served as article editor and translator) 
  • Represented a buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group (NASDAQ: CBMG), a biopharmaceutical company developing proprietary cell therapies for the treatment of cancer and degenerative diseases, in a "going private" transaction valued at approximately US$410 million
  • Represented SEEK Limited in the sale of a controlling interests in a leading Chinese recruitment website at a US$1.7 billion valuation to Primavera-led consortium
  • Represented TTM Technologies, Inc. (NASDAQ: TTMI) in the sale of substantially all of its China-based mobility business to Chinese consortium AKMMeadville Electronics (Xiamen) Co., Ltd. for a combination of $550 million in cash and an estimated $110 million in retained accounts receivable
  • Represented the buyer group in going private transaction of China XD Plastics (NASDAQ: CXDC)
  • Represented a buyer consortium led by the management in a “going private” transaction of SORL Auto Parts, Inc. (NASDAQ: SORL) valued at approximately US$96 million
  • Represented TTM Technologies, Inc. (NASDAQ: TTMI) in its $775 million acquisition of Anaren, Inc. from Veritas Capital
  • Represented the PKU-VMing (SZSE:002581) buyer consortium in a competing going private bid against management for a Chinese biopharmaceutical and vaccine company Sinovac Biotech Ltd. (NASDAQ: SVA)
  • Represented an A-share listed preclinical research company in its acquisition of a US-based CRO company
  • Represented Goldstone Investment as a member of buyer consortium in the going private transaction of Bona Film (NASDAQ: BONA)      
  • Represented the Meinian buyer consortium (SZSE:002044) in a competing going private bid against management for Chinese healthcare Company iKang Healthcare Group (NASDAQ: KANG)
VIEW MORE